Omeprazole (Risek®) Use in Inpatient and Outpatient Departments: A Post-marketing Surveillance Investigation
Omeprazole Use in Inpatient and Outpatient Departments
DOI:
https://doi.org/10.54393/pjhs.v4i04.684Keywords:
Off-Label Use, Proton Pump Inhibitors, OmeprazoleAbstract
Proton pump inhibitors (PPIs) are widely used for the treatment of acid-related gastrointestinal disorders. However, their overuse or inappropriate prescription can lead to adverse effects, increased healthcare costs, and development of antibiotic-resistant infections. Objectives: To ascertain whether the Omeprazole (Risek®)-PPIs prescription patterns by practitioners in the inpatient and outpatient departments of various healthcare facilities in Pakistan are in compliance with the therapeutic indications and to evaluate the safety profile associated with each therapeutic indication. Methods: A cross-sectional multicenter study was conducted for 4 months at various healthcare facilities inpatient and outpatient departments. A total of 1384 patients ≥ 18 years prescribed Omeprazole (Risek®) were enrolled while pregnant or lactating women, patients with chronic diarrhea, those with a history of Omeprazole allergic reaction, and with diagnosed malignancy of the GI tract were excluded. The drug use was determined based on the prescribed frequency, dosage, and duration of therapy with respect to each indication. Results: Of the total, 29.8% were already taking oral PPI or Histamine H2-Receptor Antagonists. The common indication for Omeprazole (Risek®) was Gastroesophageal Reflux Disease (GERD), followed by peptic ulcer. Mostly the drug was infused/injected in 40 mg dosage, once daily and for five days among 76.6% and 41.8%, respectively. Around 13.3% of patients experienced mild adverse events like flatulence, fever, vomiting, abdominal pain, constipation, diarrhea, nausea, rash, etc. Most off-label uses were observed in GERD concerning the duration of therapy (55.9%), prescribed frequency (19.7%), and dosage (5.9%). The Omeprazole (Risek®) treatment was also prescribed for stress ulcer prophylaxis and upper GI bleeding against the treatment protocol for the particular therapeutic indication. The adverse events were most frequent among patients with GERD, followed by NSAID-induced ulcers. Conclusions: This study provides clinical evidence on the Omeprazole (Risek®) use in concordance with the product label, in both inpatient and outpatient departments of Pakistan for various therapeutic indications.
References
Lin D, Eke C, Cai C, Thrift AP, Shukla R. Decreasing overall and inappropriate proton pump inhibitor use: perspective from a large safety-net healthcare system. Clinical Gastroenterology and Hepatology. 2020 Apr; 18(4): 763-6. doi: 10.1016/j.cgh.2019.12.015.
Strand DS, Kim D, Peura DA. 25 years of proton pump inhibitors: a comprehensive review. Gut and Liver. 2017 Jan; 11(1): 27-37. doi: 10.5009/gnl15502.
Pang SH and Graham DY. A clinical guide to using intravenous proton-pump inhibitors in reflux and peptic ulcers. Therapeutic Advances in Gastroenterology. 2010 Jan; 3(1): 11-22. doi: 10.1177/1756283X09352095.
Marks DJ. Time to halt the overprescribing of proton pump inhibitors. Clinical Pharmacist. 2016 Aug; 8(8): 1-10.
Ali O, Poole R, Okon M, Maunick S, Troy E. Irrational use of proton pump inhibitors in general practise. Irish Journal of Medical Science. 2019 May; 188: 541-4. doi: 10.1007/s11845-018-1891-1.
Forgerini M, Mieli S, Mastroianni PD. Safety assessment of omeprazole use: a review. Sao Paulo Medical Journal. 2018 Nov; 136: 557-70. doi: 10.1590/1516-3180.2018.0019220318.
Myers RP, McLaughlin K, Hollomby DJ. Acute interstitial nephritis due to omeprazole. The American Journal of Gastroenterology. 2001 Dec; 96(12): 3428-31. doi: 10.1111/j.1572-0241.2001.05345.x.
Cheema E. Investigating the association of proton pump inhibitors with chronic kidney disease and its impact on clinical practice and future research: a review. Journal of Pharmaceutical Policy and Practice. 2019 Dec; 12(1): 1-5. doi: 10.1186/s40545-019-0167-0.
Eusebi LH, Rabitti S, Artesiani ML, Gelli D, Montagnani M, Zagari RM, et al. Proton pump inhibitors: risks of long‐term use. Journal of Gastroenterology and Hepatology. 2017 Jul; 32(7): 1295-302. doi: 10.1111/jgh.13737.
van den Bemt PM, Chaaouit N, van Lieshout EM, Verhofstad MH. Noncompliance with guidelines on proton pump inhibitor prescription as gastroprotection in hospitalized surgical patients who are prescribed NSAIDs. European Journal of Gastroenterology & Hepatology. 2016 Aug; 28(8): 857-62. doi: 10.1097/MEG.0000000000000634.
Savarino V, Dulbecco P, de Bortoli N, Ottonello A, Savarino E. The appropriate use of proton pump inhibitors (PPIs): need for a reappraisal. European Journal of Internal Medicine. 2017 Jan; 37: 19-24. doi: 10.1016/j.ejim.2016.10.007.
Haastrup PF, Jarbøl DE, Thompson W, Hansen JM, Søndergaard J, Rasmussen S. When does proton pump inhibitor treatment become long term? A scoping review. BMJ Open Gastroenterology. 2021 Feb; 8(1): e000563. doi: 10.1136/bmjgast-2020-000563.
Daniels B, Pearson SA, Buckley NA, Bruno C, Zoega H. Long-term use of proton-pump inhibitors: whole-of-population patterns in Australia 2013–2016. Therapeutic Advances in Gastroenterology. 2020 Mar; 13: 1756284820913743. doi: 10.1177/1756284820913743.
Wahking RA, Steele RL, Hanners RE, Lockwood SM, Davis KW. Outcomes from a pharmacist-led proton pump inhibitor stewardship program at a single institution. Hospital Pharmacy. 2018 Feb; 53(1): 59-67. doi: 10.1177/0018578717747192.
Davis KW, Hanners RE, Lockwood SM. Implementation of a proton pump inhibitor stewardship program. American Journal of Health-System Pharmacy. 2017 Jun; 74(12): 932-7. doi: 10.2146/ajhp160670.
Koggel LM, Lantinga MA, Büchner FL, Drenth JP, Frankema JS, Heeregrave EJ, et al. Predictors for inappropriate proton pump inhibitor use: observational study in primary care. British Journal of General Practice. 2022 Dec; 72(725): e899-906. doi: 10.3399/BJGP.2022.0178.
Ahmed A and Clarke JO. Proton Pump Inhibitors (PPI). In: StatPearls. StatPearls Publishing, Treasure Island (FL); 2022.
Jaynes M and Kumar AB. The risks of long-term use of proton pump inhibitors: a critical review. Therapeutic Advances in Drug Safety. 2019 Jan; 10: 2042098618809927. doi: 10.1177/2042098618809927.
Manolis AA, Manolis TA, Melita H, Katsiki N, Manolis AS. Proton pump inhibitors and cardiovascular adverse effects: Real or surreal worries? European Journal of Internal Medicine. 2020 Feb; 72: 15-26. doi: 10.1016/j.ejim.2019.11.017.
Zhu P, Gao Z, Tang XF, Xu JJ, Zhang Y, Gao LJ, et al. Impact of proton-pump inhibitors on the pharmacodynamic effect and clinical outcomes in patients receiving dual antiplatelet therapy after percutaneous coronary intervention: a propensity score analysis. Chinese Medical Journal. 2017 Dec; 130(24): 2899-905. doi: 10.4103/0366-6999.220304.
Mandurino-Mirizzi A, Leonardi S, Melloni C. Concomitant use of proton pump inhibitors and dual antiplatelet therapy for cardiovascular outcomes. Minerva Endocrinologica. 2016 Nov; 42(3): 228-37. doi: 10.23736/S0391-1977.16.02571-2.
Guo H, Ye Z, Huang R. Clinical outcomes of concomitant use of proton pump inhibitors and dual antiplatelet therapy: a systematic review and meta-analysis. Frontiers in Pharmacology. 2021 Aug; 12: 694698. doi: 10.3389/fphar.2021.694698.
Saven H, Zhong L, McFarlane IM, McFarlane I. Co-prescription of dual-antiplatelet therapy and proton pump inhibitors: current guidelines. Cureus. 2022 Feb; 14(2): e21885. doi: 10.7759/cureus.21885.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Pakistan Journal of Health Sciences
This work is licensed under a Creative Commons Attribution 4.0 International License.
This is an open-access journal and all the published articles / items are distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. For comments
